Gene therapy helps patients with hemophilia B

December 13, 2011, National Institutes of Health

(Medical Xpress) -- An experimental gene therapy technique boosted the production of a vital blood clotting factor in six people with hemophilia B, according to new research supported by the National Institutes of Health. The therapy could give patients a long-term solution for preventing prolonged bleeding episodes and spontaneous bleeding.

People with hemophilia bleed more following trauma than people without the disease, and those with severe disease may bleed spontaneously. patients are unable to produce enough human clotting factor IX, also referred to as FIX, which is essential for normal blood clotting. are the only cells in the body capable of producing a form of factor IX that is active in the clotting process.

The study, funded in part by the NIH's National Heart, Lung, and Blood Institute (NHLBI), involved researchers joining the FIX gene to a virus that targets liver cells. This allowed the normal FIX gene to be delivered using intravenous infusion to the liver cells of patients with hemophilia B. The infusion allowed the patients to produce more FIX. The results will appear online Dec. 10 in the and in the Dec. 22 print edition. The paper will also be presented on Sunday, Dec. 11 at the American Society of Hematology's annual meeting in San Diego.

"Hemophilia has long been one of the disorders thought most likely to be correctible with , but previous approaches to deliver the gene have been disappointing. Results from this study represent a promising step toward making gene therapy a viable treatment option for hemophilia B," said Susan B. Shurin, M.D., acting director of the NHLBI. "If future studies support these findings, it would bring a significant improvement in the quality of life for those living with the disease."

Researchers from the University College London Cancer Institute, and St. Jude Children’s Research Hospital, Memphis, Tenn., led a team that examined the effects of delivering the FIX gene to patients. Scientists inserted the FIX gene into a virus, which served as the delivery vehicle for the gene therapy.

The researchers studied six people with severe hemophilia B who were producing clotting factor IX at less than 1 percent of normal levels before receiving the gene therapy. Prior to enrolling in the study, participants were receiving the standard treatment for severe hemophilia B of infusions of manufactured FIX several times a month.

The FIX gene was packaged in a modified adeno-associated virus, AAV8, which targets liver cells. After receiving the FIX gene therapy, each participant produced FIX at between 2 and 11 percent of normal levels. In the short-term follow-up period (six to 16 months), four of the six participants no longer required FIX infusions for routine bleeding. The other two participants required FIX infusions less frequently than before the study.

The unique feature of this approach is the use of AAV8 to deliver the gene to the appropriate cells. If future studies show that immunologic or other factors do not limit its long-term effectiveness, people with hemophilia B could produce their own FIX and potentially avoid reliance upon FIX infusions. While more work is needed, these results are more promising than prior attempts at gene therapy for the hemophilias.

Hemophilia B is less common than hemophilia A, a deficiency of clotting factor VIII. About 1 in 5 hemophilia patients has hemophilia B, while the other four have hemophilia A. Hemophilia is an inherited condition that affects men more frequently. Worldwide, about 1 in 5,000 men are born with hemophilia A and 1 in 25,000 men are born with B each year.

Explore further: Study first to confirm effectiveness and safety of new treatment for hemophilia

Related Stories

Study first to confirm effectiveness and safety of new treatment for hemophilia

November 2, 2011
An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events ...

Gene therapy shows promise as hemophilia treatment in animal studies

November 3, 2011
For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of ...

New method boosts blood-clotting for hemophiliacs

December 11, 2011
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated ...

Bioengineered protein shows preliminary promise as new therapy for hemophilia

October 23, 2011
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.

Genome editing improves blood clotting in mice with hemophilia B

June 28, 2011
(Medical Xpress) -- Scientists have used a gene therapy tool that acts like intelligent molecular scissors to correct the key gene defect in mice with hemophilia B, a disease that can lead to uncontrolled bleeding. The intervention ...

Recommended for you

Switch discovered to convert blood vessels to blood stem cells in embryonic development

March 20, 2018
A switch has been discovered that instructs blood vessel cells to become blood stem cells during embryonic development in mice. Using single-cell technology, researchers from the Wellcome Sanger Institute in Cambridge and ...

Scientists discover new causes of cellular decline in prematurely aging kids

March 19, 2018
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress ...

Don't blame adolescent social behavior on hormones

March 19, 2018
Reproductive hormones that develop during puberty are not responsible for changes in social behavior that occur during adolescence, according to the results of a newly published study by a University at Buffalo researcher.

Stem cells treat macular degeneration

March 19, 2018
In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD). He struggled to see things clearly, even when up close.

Measuring neutrophil motility could lead to accurate sepsis diagnosis

March 19, 2018
A microfluidic device developed by Massachusetts General Hospital (MGH) investigators may help solve a significant and persistent challenge in medicine—diagnosing the life-threatening complication of sepsis. In their paper ...

Democratizing science: Researchers make neuroscience experiments easier to share, reproduce

March 16, 2018
Over the past few years, scientists have faced a problem: They often cannot reproduce the results of experiments done by themselves or their peers.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.